Dr. Reddy's Laboratories Limited (NSE: DRREDDY)
India
· Delayed Price · Currency is INR | Market Cap | 1.12T |
| Revenue (ttm) | 299.87B |
| Net Income (ttm) | 53.33B |
| Shares Out | n/a |
| EPS (ttm) | 63.95 |
| PE Ratio | 20.97 |
| Forward PE | n/a |
| Dividend | 8.00 (0.64%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 7,492,265 |
| Open | 1,326.00 |
| Previous Close | 1,325.60 |
| Day's Range | 1,317.40 - 1,368.70 |
| 52-Week Range | 1,104.13 - 1,421.49 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 24, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Nifty 50 top gainers this week: Dr. Reddy’s Laboratories and Cipla shine amid market turmoil
The Indian equity benchmarks, Nifty 50 and Sensex, experienced their sharpest decline in four months on Friday, December 20. The Sensex tumbled 1,176 points, closing at 78,042, while the Nifty 50 drop...
Nifty 50 top gainers today on December 20: Dr. Reddy’s Laboratories, JSW Steel, ICICI Bank and more
The Indian equity market concluded on a somber note today, December 20, with indices reflecting a widespread sell-off across sectors. The Nifty 50 index slipped below the crucial 23,600 mark, while th...
Top gainers on Nifty 50: Bajaj Finance up 1.33%, Titan surges 1.43%, Dr. Reddy adds 1.9% as index gains 0.30%
The Nifty 50 rose by 72 points (+0.30%) to ₹24,023.70 as of 9:40 AM, supported by gains across major constituents. Key stocks in the spotlight include Bajaj Finance, Titan, and Dr. Reddy’s Laboratorie...
Nifty 50 top gainers today on December 19: Dr. Reddy’s Laboratories, Cipla, Bharat Petroleum and more
Indian benchmark indices continued their downward trend on December 19, marking the fourth consecutive session of losses. At the close, the Sensex dropped by 964.15 points (1.20%) to 79,218.05, while ...
Dr. Reddy’s stock jumps as Nomura upgrades to ‘Buy’ with Rs 1,500 target
Dr. Reddy’s Laboratories saw its stock jump 1% in a weak market after Nomura upgraded it to a ‘Buy’ with a target price of ₹1,500. The brokerage highlighted the stock’s underperformance and its growth...
Nomura upgrades Dr. Reddy’s to ‘Buy’, target price at Rs 1,500
Nomura has upgraded Dr. Reddy’s Laboratories to a ‘Buy’ rating, with a target price of ₹1,500/share
Nifty 50 top gainers today on December 18: Trent, Dr. Reddy’s Laboratories, Cipla and more
On December 18, Indian benchmark indices faced a decline for the third consecutive session, with the Nifty closing below the crucial 24,200 mark. The BSE Sensex fell by 502.25 points, or 0.62%, settli...
Nifty 50 top gainers today on December 16: Dr. Reddy’s Laboratories, IndusInd Bank, HDFC Life Insurance and more
Indian equity indices closed trading on December 16 with a negative note. The Sensex dropped by 384.55 points, or 0.47%, settling at 81,748.57, while the Nifty ended lower by 100.05 points, or 0.40%, ...
Pharma stocks: Sun Pharma up 1.27%, Dr. Reddy’s rises 0.82%, Cipla gains 0.53%
The pharmaceutical sector saw broad-based gains in early trade on November 29, 2024, with Cipla and Sun Pharma leading the charge. Here’s a detailed look at the top pharma stocks as of 10:34 AM: Stock...
Dr Reddy launches world's 1st immuno-onco drug for nasopharyngeal cancer in India
Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head a...
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.
Dr. Reddy’s launches Toripalimab in India, a breakthrough immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Toripalimab in India, marking the country as the third globally to access this groundbreaking immuno-oncology drug aft...
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.
Dr Reddy’s Laboratories shares fall over 2% as USFDA issues Form 483 with seven observations for Bollaram facility
Shares of Dr Reddy’s Laboratories Ltd dipped after the company announced that the US Food and Drug Administration (USFDA) issued a Form 483 with seven observations for its active pharmaceutical ingred...
Dr. Reddy’s market cap decreases by Rs 2,140 crore – Know More
Shares of Dr. Reddy’s Laboratories experienced a decline today, dropping by 2.14% to Rs 1,200.50, compared to the previous close of Rs 1,226.70. This decrease impacted the company’s market capitalizat...
Dr Reddy's Laboratories CEO on becoming a market leader in India
Erez Israeli, CEO of Dr Reddy's Laboratories highlights the moves he is undertaking to position his company as a market leader in India. He discusses the acquisition of a nicotine replacement therapy ...
Dr. Reddy's reports Q2 results
Dr. Reddy’s Laboratories shares jump 2% as company clocks highest-ever revenue in Q2
Dr. Reddy’s Laboratories (DRL) saw its shares jump more than 2% after reporting a significant 16.5% increase in revenue for Q2 FY25, reaching a record-high Rs 8,016.1 crore. Despite a 9.5% year-on-yea...
BofA expects 20% upside in Dr Reddy’s, maintains buy with target of Rs 1,530
Bank of America (BofA) has reiterated its buy rating on Dr Reddy’s Laboratories, setting a target price of ₹1,530, suggesting a 20% upside from the current market price of ₹1,276.90. The brokerage hig...
Jefferies maintains underperform on Dr Reddy’s, sees 11% downside from current share price
Jefferies has reiterated its underperform rating on Dr Reddy’s Laboratories, setting a target price of ₹1,130, implying a potential downside of 11% from the current market price of ₹1,276.90. The comp...
DRL Q2 net falls 15% despite revenue surge
HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in consolidated net profit for the Sept quarter, despite its quarterly .
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ETCompany ParticipantsRicha Periwal - Head of Investor...
Dr. Reddy's Laboratories Limited 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q2 earnings call.
Dr. Reddy's Q2 & H1FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.
Dr. Reddy’s Labs Q2 FY25 Results: Revenue grows 16.5% YoY to 8016 crore, Net Profit down 15.3%
Dr. Reddy’s Laboratories has released its consolidated financial results for the second quarter of fiscal year 2025 (Q2 FY25), reporting notable growth in revenue. The company’s board also approved a ...